SCHEMBL476464

SCHEMBL476464

COc1ccc(S(=O)(=O)c2cc(C=O)nn2-c2cccnc2F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 5/20 0.41
HSD11B1 P28845 1/20 0.37
PKM P14618 2/20 0.37
MMP2 P08253 2/20 0.37
MMP9 P14780 2/20 0.37
MMP8 P22894 2/20 0.37
MMP13 P45452 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
NPY1R P25929 1/20 0.36
POLB P06746 2/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NR1I2 O75469 1/20 0.35
HTT P42858 2/20 0.34
GLO1 Q04760 1/20 0.34
SLC40A1 Q9NP59 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3697370 0.90 NFE2L2 (0.47) NFE2L2GLO1SLC40A1LMNATSHR
SCHEMBL476434 0.88 COMT (0.40) NFE2L2HSD11B1PTGS2
SCHEMBL3703494 0.87 NFE2L2 (0.33) NFE2L2MEN1KMT2ASLC40A1
SCHEMBL476443 0.82 CA1 (0.45) NFE2L2HSD11B1PKMMMP2MMP9
SCHEMBL476451 0.82 HTR6 (0.39) NFE2L2PKMMEN1KMT2ASLC40A1
SCHEMBL476372 0.81 MMP2 (0.37) NFE2L2HSD11B1PKMMMP2MMP9
Hydrochloric Acid SCHEMBL476489 0.80 MMP2 (0.37) NFE2L2HSD11B1PKMMMP2MMP9
SCHEMBL476427 0.80 HTR6 (0.36) NFE2L2MMP2
SCHEMBL4123859 0.79 CA1 (0.35) PTGS2
SCHEMBL476502 0.79 TP53 (0.45) MMP2MMP9MMP8MMP13SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2412713-B1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-11-30 EP disclosed
US-8895588-B2 Pyrazole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-11-25 US disclosed
US-8895588-B2 Pyrazole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-11-25 US disclosed
US-8895588-B2 Pyrazole compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-11-25 US disclosed
US-20120095057-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
US-20120095057-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
US-20120095057-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
EP-2412713-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2012-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095057-A1 PYRAZOLE COMPOUND CEL, HRH2, GIPR NFE2L2 3984/4885HSD11B1 326/4885PKM 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.